JP2019176880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019176880A5 JP2019176880A5 JP2019131862A JP2019131862A JP2019176880A5 JP 2019176880 A5 JP2019176880 A5 JP 2019176880A5 JP 2019131862 A JP2019131862 A JP 2019131862A JP 2019131862 A JP2019131862 A JP 2019131862A JP 2019176880 A5 JP2019176880 A5 JP 2019176880A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- several genes
- patients
- adaptive immune
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305975 | 2012-08-06 | ||
| EP12305975.0 | 2012-08-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525857A Division JP6559566B2 (ja) | 2012-08-06 | 2013-08-05 | 癌患者をスクリーニングするための方法及びキット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019176880A JP2019176880A (ja) | 2019-10-17 |
| JP2019176880A5 true JP2019176880A5 (https=) | 2021-05-06 |
| JP6995091B2 JP6995091B2 (ja) | 2022-01-14 |
Family
ID=46762994
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525857A Active JP6559566B2 (ja) | 2012-08-06 | 2013-08-05 | 癌患者をスクリーニングするための方法及びキット |
| JP2019131862A Active JP6995091B2 (ja) | 2012-08-06 | 2019-07-17 | 癌患者をスクリーニングするための方法及びキット |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525857A Active JP6559566B2 (ja) | 2012-08-06 | 2013-08-05 | 癌患者をスクリーニングするための方法及びキット |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150218650A1 (https=) |
| EP (2) | EP2880180B1 (https=) |
| JP (2) | JP6559566B2 (https=) |
| AU (1) | AU2013301609B2 (https=) |
| CA (1) | CA2881389C (https=) |
| DK (1) | DK2880180T3 (https=) |
| ES (1) | ES2702722T3 (https=) |
| LT (1) | LT2880180T (https=) |
| PL (1) | PL2880180T3 (https=) |
| PT (1) | PT2880180T (https=) |
| SG (1) | SG11201500922RA (https=) |
| TR (1) | TR201819211T4 (https=) |
| WO (1) | WO2014023706A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR20170042778A (ko) * | 2014-08-19 | 2017-04-19 | 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 | 면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법 |
| JP2018503373A (ja) * | 2014-12-30 | 2018-02-08 | ジェネンテック， インコーポレイテッド | がんの予後診断及び治療のための方法及び組成物 |
| EP3455631B1 (en) * | 2016-05-09 | 2020-06-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for classifying patients with a solid cancer |
| TW201837467A (zh) | 2017-03-01 | 2018-10-16 | 美商建南德克公司 | 用於癌症之診斷及治療方法 |
| JP6565093B1 (ja) | 2018-03-22 | 2019-08-28 | 住友電工ハードメタル株式会社 | 表面被覆切削工具およびその製造方法 |
| WO2020072223A1 (en) * | 2018-10-01 | 2020-04-09 | Nantomics, Llc | Evidence based selection of patients for clinical trials using histopathology |
| SG11202112712RA (en) | 2019-06-03 | 2021-12-30 | Inst Nat Sante Rech Med | Methods for modulating a treatment regimen |
| WO2021092071A1 (en) | 2019-11-07 | 2021-05-14 | Oncxerna Therapeutics, Inc. | Classification of tumor microenvironments |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| EP4172628A1 (en) | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery |
| US20230235408A1 (en) | 2020-06-30 | 2023-07-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies |
| US20250035635A1 (en) | 2022-03-17 | 2025-01-30 | Institut National De La Sante Et De La Recherche Medicale | Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888278A (en) | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US6280929B1 (en) | 1986-01-16 | 2001-08-28 | The Regents Of The University Of California | Method of detecting genetic translocations identified with chromosomal abnormalities |
| US5427932A (en) | 1991-04-09 | 1995-06-27 | Reagents Of The University Of California | Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using |
| US5472842A (en) | 1993-10-06 | 1995-12-05 | The Regents Of The University Of California | Detection of amplified or deleted chromosomal regions |
| US6942970B2 (en) | 2000-09-14 | 2005-09-13 | Zymed Laboratories, Inc. | Identifying subjects suitable for topoisomerase II inhibitor treatment |
| JP2002363169A (ja) * | 2001-06-08 | 2002-12-18 | Fujiyakuhin Co Ltd | 抗腫瘍活性を有する複素環化合物 |
| US20110152115A1 (en) * | 2003-09-03 | 2011-06-23 | The United States of America, as represented by the Secretary, Department of Health and | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| EP1664762A4 (en) * | 2003-09-03 | 2008-08-13 | Us Gov Health & Human Serv | METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA |
| CA2606018A1 (en) | 2005-04-28 | 2006-11-02 | Ventana Medical Systems, Inc. | Nanoparticle conjugates |
| CA2609702C (en) | 2005-04-28 | 2013-05-28 | Ventana Medical Systems, Inc. | Antibody conjugates via heterobifunctional peg linkers |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| US20070117153A1 (en) | 2005-11-23 | 2007-05-24 | Christopher Bieniarz | Molecular conjugate |
| US20110070582A1 (en) * | 2008-11-03 | 2011-03-24 | Source Precision Medicine, Inc. d/b/d Source MDX | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects |
| PL2619576T3 (pl) * | 2010-09-24 | 2021-07-05 | Niels Grabe | Środki i sposoby do prognozowania odpowiedzi na leczenie u pacjenta chorego na nowotwór złośliwy |
| US20140018255A1 (en) * | 2011-01-11 | 2014-01-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for predicting the outcome of a cancer in a patient by analysing gene expression |
-
2013
- 2013-08-05 EP EP13745117.5A patent/EP2880180B1/en active Active
- 2013-08-05 SG SG11201500922RA patent/SG11201500922RA/en unknown
- 2013-08-05 DK DK13745117.5T patent/DK2880180T3/en active
- 2013-08-05 EP EP18196198.8A patent/EP3470531A1/en not_active Withdrawn
- 2013-08-05 ES ES13745117T patent/ES2702722T3/es active Active
- 2013-08-05 JP JP2015525857A patent/JP6559566B2/ja active Active
- 2013-08-05 AU AU2013301609A patent/AU2013301609B2/en not_active Ceased
- 2013-08-05 WO PCT/EP2013/066425 patent/WO2014023706A1/en not_active Ceased
- 2013-08-05 PL PL13745117T patent/PL2880180T3/pl unknown
- 2013-08-05 LT LTEP13745117.5T patent/LT2880180T/lt unknown
- 2013-08-05 US US14/420,053 patent/US20150218650A1/en not_active Abandoned
- 2013-08-05 PT PT13745117T patent/PT2880180T/pt unknown
- 2013-08-05 TR TR2018/19211T patent/TR201819211T4/tr unknown
- 2013-08-05 CA CA2881389A patent/CA2881389C/en active Active
-
2019
- 2019-07-17 JP JP2019131862A patent/JP6995091B2/ja active Active
-
2020
- 2020-06-09 US US16/896,736 patent/US20200299784A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019176880A5 (https=) | ||
| Arisi et al. | Circulating tumor DNA in precision oncology and its applications in colorectal cancer | |
| Kim et al. | Updates on immunotherapy and immune landscape in renal clear cell carcinoma | |
| Meng et al. | Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pancreatic adenocarcinoma | |
| Riva et al. | Multiparametric flow cytometry for MRD monitoring in hematologic malignancies: clinical applications and new challenges | |
| Dama et al. | Biomarkers and lung cancer early detection: state of the art | |
| Guo et al. | TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma | |
| Gasch et al. | Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer | |
| Johnson et al. | Phase II study of dasatinib in patients with advanced non–small-cell lung cancer | |
| Zhang et al. | CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration | |
| Lin et al. | Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet | |
| Chen et al. | Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer | |
| AU2015230677A1 (en) | Determining cancer agressiveness, prognosis and responsiveness to treatment | |
| Yim et al. | Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial | |
| JP2015530877A5 (https=) | ||
| WO2015138769A1 (en) | Methods and compositions for assessing patients with non-small cell lung cancer | |
| Kawashima et al. | Double-expressor lymphoma is associated with poor outcomes after allogeneic hematopoietic cell transplantation | |
| Fan et al. | Serum pre-albumin predicts the clinical outcome in metastatic castration-resistant prostate cancer patients treated with abiraterone | |
| Makise et al. | Squamous differentiation and prognosis in upper urinary tract urothelial carcinoma | |
| Imanishi et al. | Programmed death‐ligand 1 (PD‐L1) expression in pleomorphic carcinoma of the lung | |
| Galati et al. | Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma | |
| Szczepanski et al. | Clinical evaluation of the pancreatic cancer microenvironment: opportunities and challenges | |
| WO2024086617A3 (en) | Ph-dependent anti-cd3 antibodies and methods relating thereto | |
| Kurniali et al. | Utilization of circulating tumor cells in the management of solid tumors | |
| Haist et al. | Response to primary chemoradiotherapy of locally advanced oropharyngeal carcinoma is determined by the degree of cytotoxic T cell infiltration within tumor cell aggregates |